WeVote
Log In

Bill

Bill

HB 2614

An Act amending Title 35 (Health and Safety) of the Pennsylvania Consolidated Statutes, providing for medical devices.

2025-2026 Regular Session Introduced by Lisa Borowski and 23 co-sponsors

HB 2614 would prohibit DEHP in IV bags and tubing under Pennsylvania health and safety law, guiding a transition to DEHP-free medical devices.

Re-committed to Rules
0
WeVote Research Nonpartisan
Bill Summary · HB 2614

Overview

  • Bill: House Bill 2614 (HB 2614)
  • Session: Pennsylvania 2025-2026
  • Jurisdiction: Pennsylvania
  • Primary purpose: Amending Title 35 (Health and Safety) to address medical devices, with a memo emphasis on banning DEHP in IV bags and tubing.
  • Current status: Referred to House Health Committee on June 9, 2026. No floor votes recorded yet.

Main purpose and intent

  • The bill aims to update Pennsylvania law governing medical devices by making specific provisions within Title 35 (Health and Safety).
  • The memo accompanying the bill highlights a policy goal of banning the use of DEHP (di-2-ethylhexyl phthalate) in intravenous (IV) bags and IV tubing, reflecting concerns about potential health risks associated with DEHP in medical devices.

Key provisions and changes (as indicated by available information)

  • Amends Title 35 (Health and Safety) to establish regulations or prohibitions related to medical devices used in healthcare settings.
  • Specific focus noted in sponsor materials: prohibition of DEHP in IV bags and IV tubing.
  • The exact statutory text, definitions, enforcement mechanisms, timelines, and penalties are not fully provided in the summary materials available here; the full text (PDF) would specify:
    • Which devices and components are covered (e.g., IV bags, IV tubing) and any exemptions.
    • Applicable timelines for the phasing out or prohibition of DEHP-containing products.
    • Compliance requirements for manufacturers, healthcare facilities, and suppliers.
    • Penalties or enforcement remedies for noncompliance.
    • Regulatory oversight and implementing agencies.
    • Any consumer or patient safety standards linked to “medical devices” beyond DEHP bans.

Who would be affected

  • Healthcare facilities and providers that use IV therapy (hospitals, clinics, ambulatory surgery centers, home health, long-term care facilities).
  • Medical device manufacturers and distributors that supply DEHP-containing IV bags and tubing or related equipment.
  • Potentially patients and consumers who receive IV therapy, due to changes in the materials used in IV administration.
  • State agencies responsible for health and safety regulation, as they would oversee compliance and enforcement.

Procedural and timeline aspects

  • Introduction and sponsorship: Led by Rep. Bridget Kosierowski (primary sponsor) with a broad slate of co-sponsors from both major caucuses.
  • Committee action: Referred to the House Committee on Health on June 9, 2026.
  • Next steps: The bill would advance through committee hearings, possible amendments, and eventually floor votes in the House, followed by Senate consideration and the gubernatorial signature to become law (assuming passage in both chambers and no veto).

Potential impacts and considerations

  • Public health and safety: Limiting DEHP exposure in IV therapy aligns with safety concerns about phthalates, which have been associated with potential hormonal and reproductive effects in some studies.
  • Industry impact: Manufacturers may need to reformulate products or switch suppliers to DEHP-free materials, potentially affecting pricing, supply chains, and contract terms with healthcare facilities.
  • Implementation challenges: Compliance monitoring, labeling, and ensuring availability of DEHP-free IV products across all healthcare settings.
  • Equity considerations: Ensuring DEHP-free medical supplies are accessible and affordable for facilities of varying sizes, including rural or under-resourced providers.

Notes and what to look for in the full text

  • The exact definitions of “medical devices” covered by the act.
  • Specific prohibitions or phased deadlines for DEHP use in IV bags and tubing.
  • Regulatory agency authority, inspection, reporting, and enforcement provisions.
  • Penalties, safe harbors, and exemptions (if any).
  • Effective date and any transition periods to allow stakeholders to adapt.

For a complete understanding, review the full bill text (PDF) linked to HB 2614 and any accompanying fiscal or legal analyses released by the Pennsylvania General Assembly.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.